IQ EQ FUND MANAGEMENT IRELAND Ltd Boosts Stock Position in Tempus AI, Inc. $TEM

IQ EQ FUND MANAGEMENT IRELAND Ltd boosted its stake in Tempus AI, Inc. (NASDAQ:TEM) by 66.8% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 190,828 shares of the company’s stock after acquiring an additional 76,455 shares during the period. Tempus AI accounts for approximately 1.0% of IQ EQ FUND MANAGEMENT IRELAND Ltd’s holdings, making the stock its 21st biggest holding. IQ EQ FUND MANAGEMENT IRELAND Ltd owned 0.11% of Tempus AI worth $15,402,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Royal Bank of Canada lifted its holdings in shares of Tempus AI by 201.2% during the first quarter. Royal Bank of Canada now owns 25,988 shares of the company’s stock valued at $1,253,000 after purchasing an additional 17,359 shares during the last quarter. Rhumbline Advisers bought a new position in Tempus AI during the 1st quarter valued at approximately $116,000. Janney Montgomery Scott LLC increased its position in Tempus AI by 21.6% during the 2nd quarter. Janney Montgomery Scott LLC now owns 10,483 shares of the company’s stock valued at $666,000 after buying an additional 1,863 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in Tempus AI by 16.1% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,493 shares of the company’s stock valued at $413,000 after buying an additional 899 shares during the last quarter. Finally, QRG Capital Management Inc. bought a new stake in Tempus AI in the second quarter worth $273,000. Hedge funds and other institutional investors own 24.22% of the company’s stock.

Key Headlines Impacting Tempus AI

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Tempus highlights new growth avenues by linking hereditary-cancer datasets and immune-scoring capability to its clinical/AI platform — this expands addressable markets (germline testing + immunotherapy insights) and supports longer-term revenue upside. Read More.
• Positive Sentiment: Cathie Wood’s ARK funds bought shares of Tempus this week — a visible institutional bet that can boost demand and investor interest, especially among growth/AI-focused funds. Read More.
• Positive Sentiment: Large institutional owners have been increasing exposure over recent quarters (e.g., Vanguard additions), signaling continued institutional conviction in Tempus’s long-term thesis. Read More.
• Neutral Sentiment: Independent bullish write-ups and comparison pieces (bull case on Substack/InsiderMonkey; AAII comparison to 10x Genomics) outline upside scenarios but are opinion-driven and not new company disclosures — useful for conviction but not immediate catalysts. Read More. Read More.
• Negative Sentiment: A Tempus director sold 370 shares (small position reduction) — limited economic significance but often cited by traders as a short-term negative signal. Read More.
• Negative Sentiment: Analyst coverage remains mixed with a consensus “Hold” and several trimmed price targets — that can cap near-term upside until guidance, beats or clearer adoption metrics arrive. Read More.

Tempus AI Stock Performance

Shares of NASDAQ TEM opened at $52.44 on Friday. The firm’s 50-day moving average price is $66.82 and its 200-day moving average price is $73.78. Tempus AI, Inc. has a 52-week low of $36.22 and a 52-week high of $104.32. The company has a market cap of $9.33 billion, a PE ratio of -44.07 and a beta of 5.22. The company has a quick ratio of 3.12, a current ratio of 3.28 and a debt-to-equity ratio of 2.45.

Tempus AI (NASDAQ:TEM) last issued its quarterly earnings data on Tuesday, November 4th. The company reported ($0.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.05. Tempus AI had a negative net margin of 18.45% and a negative return on equity of 73.21%. The company had revenue of $334.21 million for the quarter, compared to the consensus estimate of $328.89 million. During the same quarter in the prior year, the firm earned ($0.46) earnings per share. The firm’s revenue for the quarter was up 84.7% compared to the same quarter last year. As a group, analysts anticipate that Tempus AI, Inc. will post -6.15 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on TEM shares. JPMorgan Chase & Co. reduced their price target on Tempus AI from $85.00 to $80.00 and set a “neutral” rating for the company in a report on Monday, December 15th. Needham & Company LLC raised their price objective on shares of Tempus AI from $70.00 to $100.00 and gave the company a “buy” rating in a research note on Wednesday, November 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tempus AI in a report on Thursday, January 22nd. Canaccord Genuity Group cut their price target on shares of Tempus AI from $95.00 to $80.00 and set a “buy” rating on the stock in a report on Monday, December 22nd. Finally, Piper Sandler decreased their price objective on shares of Tempus AI from $105.00 to $80.00 and set a “neutral” rating for the company in a report on Tuesday, November 11th. Six research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Tempus AI has an average rating of “Hold” and a consensus target price of $87.20.

Insider Transactions at Tempus AI

In other news, COO Ryan Fukushima sold 10,099 shares of the stock in a transaction on Tuesday, November 18th. The stock was sold at an average price of $65.54, for a total transaction of $661,888.46. Following the transaction, the chief operating officer directly owned 829,081 shares of the company’s stock, valued at $54,337,968.74. This represents a 1.20% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Andrew Polovin sold 12,874 shares of the company’s stock in a transaction on Monday, November 24th. The shares were sold at an average price of $75.00, for a total value of $965,550.00. Following the sale, the executive vice president owned 107,590 shares of the company’s stock, valued at approximately $8,069,250. This trade represents a 10.69% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 761,582 shares of company stock valued at $51,997,831 over the last 90 days. 26.27% of the stock is owned by corporate insiders.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.